WallStSmart

Insmed Inc (INSM)vsTarsus Pharmaceuticals Inc (TARS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 34% more annual revenue ($606.42M vs $451.36M). INSM leads profitability with a -2.1% profit margin vs -14.7%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

TARS

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.3
Piotroski: 4/9Altman Z: 1.14

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

TARS1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
128.4%10/10

Revenue surging 128.4% year-over-year

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

TARS4 concerns · Avg: 3.0/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-23.4%2/10

ROE of -23.4% — below average capital efficiency

Altman Z-ScoreHealth
1.142/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : TARS

The strongest argument for TARS centers on Revenue Growth. Revenue growth of 128.4% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : TARS

The primary concerns for TARS are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while TARS is a hypergrowth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

TARS is growing revenue faster at 128.4% — sustainability is the question.

TARS generates stronger free cash flow (13M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Tarsus Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.

Want to dig deeper into these stocks?